8-K: DiaMedica DM199 Preeclampsia Program Faces FDA Study Request

DiaMedica Therapeutics announced an update on its DM199 preeclampsia program, revealing the FDA requested an additional non-clinical study, while an ongoing Phase 2 trial shows encouraging interim data.

Summary

• DiaMedica Therapeutics completed a productive pre-IND meeting with the United States Food and Drug Administration (FDA) for its planned study evaluating DM199 in preeclampsia.
• The FDA requested one additional non-clinical, 10-day modified embryo-fetal development (EFD) and pre and postnatal Development (PPND) study in a rabbit model.
• Preparations for this additional study have commenced, with results expected to be available by the second quarter of 2026.
• Management believes the meeting minutes provide important regulatory clarity for the non-clinical package as the company prepares to submit an Investigational New Drug (IND) application for DM199 in early onset preeclampsia.
• The ongoing Phase 2 investigator-sponsored trial of DM199 in South Africa has dosed over 30 women with late-stage preeclampsia.
• Interim data from the Phase 2 trial show encouraging safety and efficacy signals, including statistically significant reductions in blood pressure and dilation of intrauterine arteries.
• Crucially, the Phase 2 interim data indicated no placental transfer of DM199, which minimizes unforeseen fetal exposure.

Sentiment

Score: 5

Explanation: The positive interim clinical data from the ongoing Phase 2 trial is encouraging, showing promising safety and efficacy signals. However, the FDA's request for an additional non-clinical study introduces a regulatory hurdle and a delay in the IND submission timeline, balancing out the positive clinical signals with increased time and cost.

Positives

• Productive pre-IND meeting with the FDA provided important regulatory clarity for the DM199 preeclampsia program.
• Ongoing Phase 2 investigator-sponsored trial in South Africa shows encouraging safety and efficacy signals.
• Interim data from the Phase 2 trial demonstrated statistically significant reductions in blood pressure and dilation of intrauterine arteries.
• No placental transfer of DM199 was observed in the Phase 2 trial, minimizing potential fetal exposure.

Negatives

• The FDA requested an additional non-clinical, 10-day modified embryo-fetal development (EFD) and pre and postnatal Development (PPND) study in a rabbit model.
• Results for the newly requested additional study are not expected until the second quarter of 2026, which will extend the timeline for IND submission and subsequent clinical trials in the U.S.

Risks

• Risks and uncertainties related to the timing and outcomes of non-clinical studies.
• Risks and uncertainties relating to the timing of studies and trials.
• Risks and uncertainties relating to the clinical expansion into preeclampsia and associated trials.
• The risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials.
• DiaMedica's plans to develop, obtain regulatory approval for and commercialize its DM199 product candidate for the treatment of preeclampsia and acute ischemic stroke and its expectations regarding the benefits of DM199.
• DiaMedica's ability to conduct successful clinical testing of DM199 and within its anticipated parameters, site activations, enrollment numbers, costs and timeframes.
• The perceived benefits of DM199 over existing treatment options.
• The potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs and worldwide global supply chain shortages on DiaMedica's business and clinical trials.
• DiaMedica's reliance on collaboration with third parties to conduct clinical trials.
• DiaMedica's ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals for DM199 for preeclampsia and acute ischemic stroke.
• Risks identified under the heading Risk Factors in DiaMedica's annual report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent SEC reports.

Future Outlook

Management anticipates ongoing engagement with the FDA to advance efforts for a novel preeclampsia treatment. Results from the additional non-clinical study are expected by the second quarter of 2026, which will inform the Investigational New Drug (IND) submission for DM199 in early onset preeclampsia. The company also expects continued progress in the ongoing Phase 2 investigator-sponsored trial in South Africa.

Management Comments

• "We believe the meeting minutes provide important regulatory clarity on our non-clinical package as we prepare to submit an IND for the study of DM199 in patients with early onset preeclampsia." Rick Pauls, President and CEO of DiaMedica.
• "We look forward to ongoing engagement with the FDA as we advance efforts to develop a novel treatment for women suffering from this devastating condition, which is one of the leading causes of maternal and neonatal morbidity and mortality worldwide." Rick Pauls, President and CEO of DiaMedica.
• "Interim data show encouraging safety and efficacy signals, including statistically significant reductions in blood pressure and dilation of intrauterine arteries, and importantly, with no placental transfer of DM199, thereby minimizing unforeseen fetal exposure." Dr. Julie Krop, Chief Medical Officer of DiaMedica.

Industry Context

Preeclampsia is a severe condition globally, contributing significantly to maternal and neonatal morbidity and mortality, highlighting a critical unmet medical need. DiaMedica's DM199, a recombinant form of human tissue kallikrein-1 (rhKLK1), represents a novel therapeutic approach, leveraging KLK1's established role in vascular diseases, particularly in Asia, to address this devastating condition.

Stakeholder Impact

• Shareholders: Potential for increased value if DM199 progresses successfully, but also risk of delays and increased costs due to the additional study. Positive interim data could boost confidence.
• Patients (women with preeclampsia): Hope for a novel treatment option, but potential delays in availability due to regulatory requirements.
• Healthcare Providers: Potential for a new tool to manage preeclampsia if approved.
• Employees: Continued work on a promising drug candidate, but with extended timelines for regulatory milestones.

Next Steps

• Complete the additional non-clinical, 10-day modified EFD and PPND study in a rabbit model.
• Receive results from the additional non-clinical study by the second quarter of 2026.
• Submit an Investigational New Drug (IND) application for DM199 in early onset preeclampsia.
• Continue the ongoing Phase 2 investigator-sponsored trial of DM199 in South Africa.
• Maintain ongoing engagement with the FDA regarding the DM199 program.

Key Dates

Recommendation

The positive interim clinical data from the South Africa trial is encouraging, showing promising safety and efficacy signals for DM199 in preeclampsia. However, the FDA's request for an additional non-clinical study introduces a regulatory hurdle and a delay in the IND submission timeline, pushing back potential U.S. clinical trials. This creates a mixed signal, suggesting a 'hold' position until the results of the additional study are available and the path forward for IND submission becomes clearer. The company also highlights the need for continued funding, which is a common risk for clinical-stage biotechs.

Keywords

DiaMedica Therapeutics, DMAC, DM199, rinvecalinase alfa, preeclampsia, FDA, IND, clinical trial, biopharmaceutical, KLK1, fetal growth restriction, acute ischemic stroke, maternal health, drug development